Table 4.
Subgroup analyses of the models in single-positive patients
|
|
Rad-score 1
|
Rad-score 2
|
P
value
|
||||
|
Subgroups
|
AUC
|
SEN (%)
|
SPE (%)
|
AUC
|
SEN (%)
|
SPE (%)
|
|
| nCRT | |||||||
| With (n = 77) | 0.740 (95%CI: 0.628-0.833) | 73.5% | 74.4% | 0.897 (95%CI: 0.806-0.954) | 73.5% | 90.7% | 0.014 |
| Without (n = 127) | 0.753 (95%CI: 0.668-0.825) | 60% | 86.1% | 0.957 (95%CI: 0.905-0.985) | 89.1% | 93.1% | < 0.001 |
| Location | |||||||
| Mid-low (n = 139) | 0.782 (95%CI: 0.704-0.848) | 75.4% | 62.2% | 0.931 (95%CI: 0.875-0.967) | 86.2% | 82.4% | < 0.001 |
| High (n = 65) | 0.643 (95%CI: 0.515-0.758) | 54.2% | 73.2% | 0.941 (95%CI: 0.853-0.984) | 83.3% | 85.4% | < 0.001 |
| Number of TDs | 1-2 (n = 50) | ≥ 3 (n = 39) | P = 0.838 | 1-2 (n = 50) | ≥ 3 (n = 39) | P = 0.309 | |
| Value | 0.64 ± 0.24 | 0.65 ± 0.22 | 0.83 ± 0.22 | 0.77 ± 0.26 | |||
Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; TDs: Tumor deposits; AUC: Area under the curve; SEN: Sensitivity; SPE: Specificity; nCRT: Neoadjuvant chemoradiotherapy.